Literature DB >> 21172884

Durable remission of metastatic renal cell carcinoma with gemcitabine and capecitabine after failure of targeted therapy.

Stephen L Richey1, Chaan Ng, Zita D Lim, Eric Jonasch, Nizar M Tannir.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21172884      PMCID： PMC4468428          DOI： 10.1200/JCO.2010.31.6091

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  18 in total

1.  Induction of apoptosis in fibroblasts by c-myc protein.

Authors:  G I Evan; A H Wyllie; C S Gilbert; T D Littlewood; H Land; M Brooks; C M Waters; L Z Penn; D C Hancock
Journal:  Cell       Date:  1992-04-03       Impact factor: 41.582

2.  Sorafenib in advanced clear-cell renal-cell carcinoma.

Authors:  Bernard Escudier; Tim Eisen; Walter M Stadler; Cezary Szczylik; Stéphane Oudard; Michael Siebels; Sylvie Negrier; Christine Chevreau; Ewa Solska; Apurva A Desai; Frédéric Rolland; Tomasz Demkow; Thomas E Hutson; Martin Gore; Scott Freeman; Brian Schwartz; Minghua Shan; Ronit Simantov; Ronald M Bukowski
Journal:  N Engl J Med       Date:  2007-01-11       Impact factor: 91.245

3.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

Authors:  Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Olivier Rixe; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Sindy T Kim; Isan Chen; Paul W Bycott; Charles M Baum; Robert A Figlin
Journal:  N Engl J Med       Date:  2007-01-11       Impact factor: 91.245

4.  A phase II study of gemcitabine and capecitabine in metastatic renal cancer: a report of Cancer and Leukemia Group B protocol 90008.

Authors:  Walter M Stadler; Susan Halabi; Brian Rini; Marc S Ernstoff; Enrique Davila; Joel Picus; Robert Barrier; Eric J Small
Journal:  Cancer       Date:  2006-09-15       Impact factor: 6.860

5.  Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.

Authors:  Bernard Escudier; Anna Pluzanska; Piotr Koralewski; Alain Ravaud; Sergio Bracarda; Cezary Szczylik; Christine Chevreau; Marek Filipek; Bohuslav Melichar; Emilio Bajetta; Vera Gorbunova; Jacques-Olivier Bay; Istvan Bodrogi; Agnieszka Jagiello-Gruszfeld; Nicola Moore
Journal:  Lancet       Date:  2007-12-22       Impact factor: 79.321

6.  Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis.

Authors:  Eric Jonasch; Paul Corn; Lance C Pagliaro; Carla L Warneke; Marcella M Johnson; Pheroze Tamboli; Chaan Ng; Ana Aparicio; Robynne G Ashe; John J Wright; Nizar M Tannir
Journal:  Cancer       Date:  2010-01-01       Impact factor: 6.860

7.  A phase ii study of gemcitabine and capecitabine in patients with advanced renal cell cancer: Southwest Oncology Group Study S0312.

Authors:  Peter J Van Veldhuizen; Michael Hussey; Primo N Lara; Philip C Mack; Regina Gandour-Edwards; Joseph I Clark; Marianne K Lange; David E Crawford
Journal:  Am J Clin Oncol       Date:  2009-10       Impact factor: 2.339

8.  A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents.

Authors:  Nizar M Tannir; Peter F Thall; Chaan S Ng; Xuemei Wang; Leiko Wooten; Arlene Siefker-Radtke; Paul Mathew; Lance Pagliaro; Christopher Wood; Eric Jonasch
Journal:  J Urol       Date:  2008-07-17       Impact factor: 7.450

9.  Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.

Authors:  Gary Hudes; Michael Carducci; Piotr Tomczak; Janice Dutcher; Robert Figlin; Anil Kapoor; Elzbieta Staroslawska; Jeffrey Sosman; David McDermott; István Bodrogi; Zoran Kovacevic; Vladimir Lesovoy; Ingo G H Schmidt-Wolf; Olga Barbarash; Erhan Gokmen; Timothy O'Toole; Stephanie Lustgarten; Laurence Moore; Robert J Motzer
Journal:  N Engl J Med       Date:  2007-05-31       Impact factor: 91.245

10.  Phase II clinical trial of capecitabine and gemcitabine chemotherapy in patients with metastatic renal carcinoma.

Authors:  J S Waters; C Moss; L Pyle; M James; S Hackett; R A'hern; M Gore; T Eisen
Journal:  Br J Cancer       Date:  2004-11-15       Impact factor: 7.640
View more
  9 in total

Review 1.  Chinese guidelines on the management of renal cell carcinoma (2015 edition).

Authors:  Jun Guo; Jianhui Ma; Yan Sun; Shukui Qin; Dingwei Ye; Fangjian Zhou; Zhisong He; Xinan Sheng; Feng Bi; Dengfeng Cao; Yingxia Chen; Yiran Huang; Houjie Liang; Jun Liang; Jiwei Liu; Wenchao Liu; Yueyin Pan; Yongqian Shu; Xin Song; Weibo Wang; Xiuwen Wang; Xiaoan Wu; Xiaodong Xie; Xin Yao; Shiying Yu; Yanqiao Zhang; Aiping Zhou
Journal:  Ann Transl Med       Date:  2015-11

2.  Intrinsic resistance to tyrosine kinase inhibitors is associated with poor clinical outcome in metastatic renal cell carcinoma.

Authors:  Jonas Busch; Christoph Seidel; Steffen Weikert; Ingmar Wolff; Carsten Kempkensteffen; Lisa Weinkauf; Stefan Hinz; Ahmed Magheli; Kurt Miller; Viktor Grünwald
Journal:  BMC Cancer       Date:  2011-07-14       Impact factor: 4.430

3.  Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy.

Authors:  D Y Heng; M J Mackenzie; U N Vaishampayan; G A Bjarnason; J J Knox; M H Tan; L Wood; Y Wang; C Kollmannsberger; S North; F Donskov; B I Rini; T K Choueiri
Journal:  Ann Oncol       Date:  2011-11-05       Impact factor: 32.976

4.  Phase II trial of pemetrexed plus gemcitabine in patients with locally advanced and metastatic nonclear cell renal cell carcinoma.

Authors:  Stephen L Richey; Pheroze Tamboli; Chaan S Ng; E Lin; Zita D Lim; John C Araujo; Eric Jonasch; Padmanee Sharma; Lance C Pagliaro; Nizar M Tannir
Journal:  Am J Clin Oncol       Date:  2013-10       Impact factor: 2.339

Review 5.  Adjuvant therapy for renal cell carcinoma: past, present, and future.

Authors:  Sumanta K Pal; Naomi B Haas
Journal:  Oncologist       Date:  2014-06-26

6.  Prognostic factors of metastatic renal cell carcinoma with extensive sarcomatoid component.

Authors:  Inkeun Park; Yong Mee Cho; Jae-Lyun Lee; Jin-Hee Ahn; Dae-Ho Lee; Cheryn Song; Jun-Hyuk Hong; Choung-Soo Kim; Hanjong Ahn
Journal:  J Cancer Res Clin Oncol       Date:  2013-02-09       Impact factor: 4.553

7.  Delivering preventive, predictive and personalised cancer medicine for renal cell carcinoma: the challenge of tumour heterogeneity.

Authors:  Rosalie Fisher; James Larkin; Charles Swanton
Journal:  EPMA J       Date:  2011-12-22       Impact factor: 6.543

8.  Management of metastatic renal cell carcinoma - mini review.

Authors:  Anubha Bharthuar; Himanshu Pandey; Swapan Sood
Journal:  J Kidney Cancer VHL       Date:  2015-05-05

9.  Gemcitabine induced hemolytic uremic syndrome.

Authors:  Seyed-Ali Sadjadi; Pavan Annamaraju
Journal:  Am J Case Rep       Date:  2012-05-25
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.